Celcuity (CELC) to Release Quarterly Earnings on Thursday

Celcuity (NASDAQ:CELC – Get Free Report) will issue its quarterly earnings data after the market closes on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.65) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link. Celcuity (NASDAQ:CELC – Get [...]

featured-image

Celcuity ( NASDAQ:CELC – Get Free Report ) will issue its quarterly earnings data after the market closes on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.65) per share for the quarter.

Individual that wish to listen to the company’s earnings conference call can do so using this link . Celcuity ( NASDAQ:CELC – Get Free Report ) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.



62) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.09.

During the same period in the prior year, the firm earned ($0.66) EPS. On average, analysts expect Celcuity to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Celcuity Stock Performance NASDAQ CELC opened at $14.94 on Wednesday. The company has a fifty day moving average price of $15.

25 and a 200-day moving average price of $16.08. The firm has a market cap of $553.

23 million, a price-to-earnings ratio of -5.45 and a beta of 0.76.

The company has a debt-to-equity ratio of 0.54, a current ratio of 14.95 and a quick ratio of 14.

95. Celcuity has a 1 year low of $10.43 and a 1 year high of $22.

19. Wall Street Analyst Weigh In Read Our Latest Analysis on Celcuity Celcuity Company Profile ( Get Free Report ) Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.

See Also Five stocks we like better than Celcuity Find and Profitably Trade Stocks at 52-Week Lows Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025 What is an Earnings Surprise? Is Tesla’s Valuation a Bubble or Backed by Real Growth? How to invest in marijuana stocks in 7 steps Trucking Stocks Led the Pack Last Week: Can They Keep Rolling? Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter ..